Dr. Brian Loggie
Chief of the Division of Surgical Oncology
Creighton University Medical Center-Bergan Mercy
Division of Surgical Oncology
Omaha, NE 68124
The surgeon or staff member will make their best effort to call you at your requested time. If they become unavailable, you will receive a text/email to reschedule.
Schedule a Conversation
Dr. Loggie featured in Live Well Nebraska
HIPEC Article in Omaha World-Herald, March 2018
Pam Boruff is in remission after battling cancer of the abdominal lining. She is a patient of Dr. Brian Loggie at Creighton University Medical Center. Dr. Loggie treated Pam using hyperthermic intraperitoneal chemotherapy or HIPEC. Dr. Loggie helped to pioneer this treatment in the 1990 and he is hoping that new research studies will help this treatment become a more common practice that will help to extend the lives of many cancer patients with cancer in the abdominal area.
Read the Article:
Anderson, Julie. “Omaha Docs Hope ‘Hot Chemo’ Trial Will Lead to Wider Use of Treatment.” Omaha.com, 5 Mar. 2018, www.omaha.com/livewellnebraska/plus/omaha-docs-hope-hot-chemo-trial-will-lead-to-wider/article_d5ed79b2-a94f-597e-97fc-cfcb0dbca6ff.html.
Dr. Brian W. Loggie currently serves as the Harold J. Bonnstetter Professor of Surgery at Creighton University School of Medicine located in Omaha, Nebraska and is chief of the division of surgical oncology and director of the Cancer Biology Program at Creighton University Medical Center. Dr. Loggie attended Loyola College in Montreal, Canada prior to completing his medical degree at McGill University, also located in Montreal. He completed his residency at Montreal General Hospital from 1980-1986 followed by a clinical and research fellowship in surgical oncology at the University of Illinois at Chicago from 1986-1988.
Prior to assuming his leadership roles at Creighton in 2002, Dr. Loggie held faculty positions at the University of Illinois at Chicago (1986-1988), the Bowman Gray School of Medicine in Winston-Salem, North Carolina (1988-2000), and the University of Texas Southwestern Medical Center in Dallas, Texas (2000-2002).
Dr. Loggie is internationally-renowned for his expertise and clinical experience in treating cancers that are metastatic to or that have originated in the peritoneal lining (thin tissue layer) of the abdomen and pelvis. He is a pioneer in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment—a procedure in which a chemotherapy solution is heated to a temperature greater than normal body temperature and delivered directly to the abdominal cavity.
Board-certified by the American Board of Surgery, Dr. Loggie is an expert in surgical oncology. Among the conditions that he specializes in are peritoneal mesothelioma, peritoneal carcinomatosis and malignant ascites, cutaneous malignant melanoma, pseudomyxoma peritonei, and abdominopelvic and retroperitoneal sarcomas.
Dr. Loggie is a fellow of the Royal College of Surgeons of Canada, the Society of Surgical Oncology (SSO), the American College of Surgeons (ACS), and the Southeastern Surgical Congress (SESC). His professional societal memberships include, but are not limited to, the Canadian Association of General Surgeons (CAGS), the Association for Academic Surgery (AAS), the American Medical Association (AMA), the Southern Association for Oncology (SAO), and the American Society of Clinical Oncology (ASCO).
Clinical Research and Publications
Dr. Loggie has assembled a clinical and translational research team at Creighton with a particular focus on identifying innovative and more effective treatments for malignant peritoneal mesothelioma and pseudomyxoma peritonei (PMP)—a rare and slow-growing form of cancer that usually originates in the appendix or ovaries.
Dr. Loggie has coauthored several scientific, peer-reviewed articles that have been published in such journals as The American Surgeon, the Journal of Surgical Oncology, World Journal of Surgical Oncology, Annals of Surgical Oncology, among others. Articles that he is coauthored with a particular focus on mesothelioma include the following:
- Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014 Apr;80(4):348-52.
- Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol. 2010 Oct 13;8:88.
- Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol. 2009 Jan;16(1):152-8. Epub 2008 Nov 8.
Have some Questions?
The contact form located on this page is the best way to get in touch with Dr. Brian Loggie concerning a personalized HIPEC conversation. The surgeon or their office will make every effort to contact you as soon as possible.
To have a conversation about the HIPEC procedure you do not need a referral from a doctor. There is no charge for an initial conversation.
View Contact Information
Phone: 402 280 3448